DMDavid Michael Miller

David Michael Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Michael Miller has a total of 330 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Authorship Begins Before the Byline

    by David Michael Miller, Elizabeth I. Buchbinder, Juliane Andrade Czapla, Kevin Scott Emerick, Howard Lane Kaufman, Vishal Anil Patel, Kenneth Y. Tsai, Michael K. Wong

  • Neoadjuvant Intralesional Daromun in Resectable Melanoma: Interpreting the PIVOTAL Trial

    by David Michael Miller, Elizabeth I. Buchbinder, Isaac Brownell, Karam Khaddour, Nikhil I. Khushalani, Justine V. Cohen, Vishal Anil Patel, Michael K. Wong

  • Immune Checkpoint Inhibitors for Advanced Periocular/Orbital Squamous Cell Carcinoma of Cutaneous Origin: Durable Responses in a Retrospective Cohort

    by Amee D. Azad, Jia Jia Zhang, Kevin S. Emerick, Sophia Z. Shalhout, Howard L. Kaufman, David M. Miller, Ross D. Merkin, Nahyoung G. Lee, Michael K. Yoon, Suzanne K. Freitag, et al.

    Purpose: This study’s purpose was to investigate the outcomes of immune checkpoint inhibitor (ICI) treatment of periocular cutaneous squamous cell carcinoma with orbital invasion. Methods: A retrospective review was performed of 19 patients with biopsy-confirmed, advanced periocular cutaneous squamous cell carcinoma with orbital invasion treated with ICIs at a single institution. Tumors of conjunctival, sinonasal, lacrimal sac, or indeterminate origin were excluded. Demographic and clinical features at presentation, duration (number of cycles) of ICI, and treatment response were analyzed. Results: Nineteen patients with periocular cutaneous squamous cell carcinoma with orbital invasion treated with ICI were identified. The median age at diagnosis was 74 (interquartile range, 67–78) years. Most patients were non-Hispanic White (95%, n=18) and male (68%, n=13). Eight patients (42%) had AJCC T4 disease. Median presenting logMAR visual acuity in the affected eye was 0.3 (0.2–0.8). Eighteen patients (95%) had orbital involvement, and 14 (74%) had perineural involvement. Thirteen (68%) were treated with cemiplimab and 5 (26%) with pembrolizumab, and 1 was transitioned to cemiplimab after progression on pembrolizumab. Patients received a median of 9 (interquartile range, 6–15) cycles. Nine patients (47%) had complete response, 6 (32%) had a partial response, 3 (16%) remained stable, and only 1 (6%) progressed on ICIs. No tumors recurred nor required exenteration by the end of the study period. The median follow-up time was 35 (interquartile range, 19–53) months. Conclusions: Immunotherapy demonstrated excellent, sustained clinical outcomes in periocular cutaneous squamous cell carcinoma with orbital invasion with low morbidity and mortality. A disease control rate of over 90% was achieved and sustained at a median follow-up of almost 3 years.

  • Open Access

    Frontline immunotherapy with response-guided subsequent treatment (FIRST) in cutaneous squamous cell carcinoma: a Bayesian causal analysis of dose intensity, early benefit, and treatment de-escalation

    by David M Miller, Ross D Merkin, Howard L Kaufman, Sameer G Gupta, Natalie Wolkow, Adewunmi Adelaja, Ryan J Sullivan, Chirayu Patel, Alexandra Sorrentino, Sonia Cohen, et al.

    Background: Programmed death receptor 1 (PD-1) blockade produces high response rates in resectable and locally advanced cutaneous squamous cell carcinoma (CSCC), but how many doses are needed and whether surgery or radiation after immunotherapy (consolidation) adds benefit in deep responders (patients with substantial clinical responses) remain unclear. Observational inference is challenging because treatment decisions are response-guided, doses accumulate over time, and treatment selection depends on patient characteristics that also affect outcomes. Methods: We conducted a retrospective cohort study of 189 patients with resectable, borderline-resectable, locally advanced, or limited metastatic CSCC treated with immune checkpoint inhibitors as part of management (2019–2025). We summarized responses, treatment discontinuation patterns, and time-to-event outcomes. To evaluate dose-response relationships, we fit Bayesian regression models adjusting for prespecified baseline confounders. Directed acyclic graphs were used to formalize causal assumptions and identify minimally sufficient adjustment sets. For event-free survival (EFS), we used a prespecified landmark analysis among patients receiving ≥2 doses to reduce guarantee-time bias. Results: Objective response occurred in 119/189 (63%), including 52/189 (27.5%) complete responses. Nearly half of patients received ≤2 doses (92/189, 48.7%). Among 50 complete responders managed without surgery, 1 recurrence was observed over a median follow-up of 25.4 months. Dose-response models showed a consistent but modest positive association between additional doses and response: in a linear model, each additional dose was associated with ~1.09 fold higher odds of response (posterior probability >95%). Flexible threshold models suggested early concentration of benefit, strongest at 2 versus 1 dose (93.6% posterior probability of benefit), with persistent uncertainty in effect magnitude (66% probability of ≥6 percentage-point absolute increase). In the EFS landmark modeling cohort (n=177), receipt of ≥3 versus 2 doses showed a 93% posterior probability of reduced event risk, but the 89% credible interval spanned the null (HR 0.61–1.01), indicating substantial uncertainty regarding incremental downstream benefit. Conclusions: In real-world CSCC, durable disease control frequently occurred after limited immunotherapy exposure, and clinical responders often did well without routine surgical consolidation. Although additional doses may modestly improve outcomes, observed gains appear concentrated early with uncertain incremental value beyond two doses. These patterns support conceptualizing treatment as frontline immunotherapy with response-guided subsequent treatment rather than fixed-duration neoadjuvant therapy.


  • Open Access

    Local Recurrence After Excision of Merkel Cell Carcinoma: What Do We Actually Know, and What Should We Do Next?

    by David Miller, Kevin Emerick, Howard Kaufman, Aubriana McEvoy, Lisa Zaba, Ajay Sharma, Adewunmi Adelaja, Ann Silk, Nikhil Khushalani, Isaac Brownell, et al.

    This Perspectives on the Science article summarizes a multidisciplinary Society of Cutaneous Oncology Journal Club discussion of Kavanagh et al., Local Recurrence Following Complete Surgical Excision of Primary Merkel Cell Carcinoma. The discussion examines uncertainty in local recurrence risk after margin-negative excision, variation in postoperative radiation therapy practice, and future evidence-generation approaches that integrate curated multi-institutional data, causal inference, and probabilistic modeling to support decision-making under uncertainty.

  • Open Access

    Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF -mutant advanced melanoma: A matching-adjusted indirect comparison

    by David M Miller, James W Smithy, Jennell Palaia, Divya Patel, Anthony Salvatore, David D’aDamo, Matthew Mattera, Zheng-Yi Zhou, Viviana Garcia-Horton, Ahmad A Tarhini

    Background: Dual immuno-oncology (IO) therapy or BRAF/MEK inhibitor combinations are approved first-line (1L) treatment options for BRAF- mutant advanced melanoma. In the absence of head-to-head trials comparing 1L nivolumab plus relatlimab (NIVO+RELA) to BRAF/MEK inhibitors, we compared its efficacy to dabrafenib+trametinib (DAB+TRAM), encorafenib+binimetinib (ENCO+BINI), vemurafenib+cobimetinib (VEM+COBI) and atezolizumab (ATEZO)+VEM+COBI using matching-adjusted indirect comparisons (MAICs). Methods: Patient-level data for NIVO+RELA from the RELATIVITY-047 trial ( BRAF -mutant subset) and aggregate data from the COMBI-d/v, COLUMBUS, coBRIM and IMspire150 trials were used. Adults with untreated BRAF- mutant advanced melanoma receiving 1L therapy were included. Separate unanchored MAICs were conducted to compare outcomes between NIVO+RELA versus comparators. MAICs matched on baseline characteristics per data availability and clinical relevance (age, sex, metastatic stage, prior IO, brain metastases, tumour size, etc.). Overall survival (OS) and investigator-assessed progression-free survival (PFS) were compared using weighted Cox proportional hazards models and, due to violation of the proportional hazards assumption, interval Cox models with boundaries at 12 (doublets) or 24 (ATEZO+VEM+COBI) months from treatment initiation. Investigator-assessed overall response rate (ORR) and safety outcomes (any adverse event (AE), grade 3/4 AEs, AEs leading to discontinuation, specific AEs) were compared via ORs and risk differences (RDs), respectively. Results: BRAF -mutant patients from RELATIVITY-047 (n=136) were matched to patients who received DAB+TRAM (n=563), ENCO+BINI (n=192), VEM+COBI (n=247) or ATEZO+VEM+COBI (n=256). Post-matching, NIVO+RELA was associated with longer OS after 12 months versus DAB+TRAM (HR (95% CI) 0.47 (0.31 to 0.70)), ENCO+BINI (0.51 (0.32 to 0.83)) and VEM+COBI (0.41 (0.26 to 0.62)) and at any time versus ATEZO+VEM+COBI (0.68 (0.48–0.98)). PFS was shorter versus DAB+TRAM (1.36 (0.96 to 1.94)), ENCO+BINI (1.72 (1.13 to 2.61)) and VEM+COBI (1.27 (0.89 to 1.81)) in the first 12 months but favoured NIVO+RELA after 12 months (0.56 (0.33 to 0.93), 0.63 (0.28 to 1.45) and 0.41 (0.24 to 0.70)). PFS was similar versus ATEZO+VEM+COBI through 24 months (1.21 (0.87 to 1.68)) and favoured NIVO+RELA beyond 24 months (0.45 (0.19 to 1.07)). ORR was lower with NIVO+RELA versus all comparators. Grade 3/4 AEs were less frequent with NIVO+RELA versus DAB+TRAM (RD (95% CI) −20.1% (−30.6 to −9.5)), ENCO+BINI (−29.2% (-42.2 to −16.3)), VEM+COBI (−36.9% (−47.5 to −26.3)) and ATEZO+VEM+COBI (percentage: 40.0% vs 74.9%). Conclusions: These MAICs suggest that 1L dual IO therapy with NIVO+RELA confers a long-term OS advantage in BRAF -mutant advanced melanoma compared with BRAF/MEK inhibitor combinations despite lower ORR, consistent with prior evidence for 1L NIVO+IPI in this setting. As unanchored analyses, potential residual confounding remains, and results should be interpreted cautiously.


  • Open Access

    Dual Checkpoint Blockade in Merkel Cell Carcinoma: Lessons from CheckMate 358 and the Questions That Remain

    by David Michael Miller, Vernon Sondak, Sunandana Chandra, Vatche Tchekmedyian, Ryan Sullivan, Ross Merkin, Vishal Patel, Adewole Adamson, Isaac Brownell, Reed Drews, et al.

    A multidisciplinary summary and perspective on the CheckMate 358 trial in advanced Merkel cell carcinoma, exploring the role of dual checkpoint blockade, challenges of trial interpretation, real-world practice patterns, and evolving views on therapeutic intent and long-term outcomes.


  • The evolving treatment landscape for CSCC

    by David M. Miller

    The treatment landscape for cutaneous squamous cell carcinoma (CSCC) is evolving, with immunotherapy transforming care across all stages of disease and expanding the role of dermatologists. While surgery and radiotherapy remain cornerstones for localized CSCC, immune checkpoint inhibitors (ICIs) offer durable responses and survival benefits in advanced cases. Emerging approaches, including neoadjuvant, adjuvant, and intralesional ICIs, provide dermatologists with opportunities to integrate these therapies into practice, potentially enhancing surgical outcomes and preserving function in high-risk, resectable CSCC. Preliminary data on anti-PD-1 therapy as a preventive strategy for actinic neoplasia syndrome introduces new avenues for long-term management, though further evidence is needed. As systemic immunotherapy becomes increasingly relevant in dermatology, addressing immunotherapy-related adverse events requires interdisciplinary collaboration and specialized training. These advancements emphasize the expanding responsibilities of dermatologists in CSCC management while highlighting the importance of continued research and thoughtful application of these therapies.


  • Open Access

    Evolving Standards for Resected High-Risk CSCC: Integrating Insights from C-POST and KEYNOTE-630

    by David Michael Miller, Vishal Patel, Vernon Sondak, Vatche Tchekmedyian, Ross Merkin, Isaac Brownell, Reed Drews, Sameer Gupta, Nikhil Khushalani, Paul Nghiem, et al.

    This perspective summarizes a multidisciplinary discussion of the C-POST trial, which demonstrated improved disease-free survival with adjuvant cemiplimab in patients with resected high-risk cutaneous squamous cell carcinoma (CSCC). Participants reflected on evolving practice patterns and considered the contrasting futility outcome of adjuvant pembrolizumab in the KEYNOTE-630 study. To help explore potential reasons for these divergent results, this piece incorporates reconstructed survival data—estimates derived from published Kaplan-Meier curves in the absence of individual patient data. The discussion underscores both the enthusiasm and the remaining uncertainty surrounding adjuvant immunotherapy in CSCC.